Delta Sleep-Inducing Peptide
Also known as: DSIP, Delta sleep peptide, Sleep-inducing peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
1 notable study · 2 references
TLDR
DSIP is a nine-amino-acid peptide originally identified through sleep research and subsequently studied for sleep, stress, neuroendocrine regulation, pain, and neurological effects, but decades of inconsistent evidence have not established it as a simple endogenous sleep hormone or a proven insomnia treatment.
At a Glance
Classification: Synthetic nonapeptide; experimental neuropeptide; sleep/stress-regulation research peptide
Delta Sleep-Inducing Peptide—DSIP—is a nine-amino-acid peptide: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu It was originally isolated in the 1970s during experiments investigating substances associated with sleep. That history produced one of the catchiest names in peptide research: Delta Sleep-Inducing Peptide. Unfortunately, the name is considerably more definitive than the evidence. DSIP has been investigated for: • Sleep architecture • Insomnia • Circadian regulation • Stress responses • Pain • Neuroendocrine signaling • Cortisol/ACTH pathways • Withdrawal states • Epilepsy But decades of research have not established DSIP as a simple endogenous sleep hormone. Some experiments reported sleep-promoting effects. Others produced inconsistent or contradictory findings. The result is a fascinating research peptide with a name that has dramatically outlived the certainty of the original hypothesis.
What Is Delta Sleep-Inducing Peptide?
DSIP was first identified during experiments in which cerebral venous blood from sleeping rabbits was examined for sleep-associated substances. Researchers isolated a small peptide that appeared capable of influencing sleep in recipient animals. The peptide was named: Delta Sleep-Inducing Peptide because early experiments suggested an association with delta-wave slow-wave sleep. That led initially to the hypothesis that DSIP might represent an endogenous sleep-promoting substance. Later research complicated the picture substantially. DSIP has been reported in various tissues and biological systems, but its: • physiological source, • receptor, • endogenous concentrations, • metabolic pathway, • and actual role in normal sleep remain surprisingly uncertain.
What Are Researchers Studying?
Sleep architecture
Sleep is the obvious starting point. Early animal studies suggested DSIP could increase slow-wave or delta sleep. Human experiments subsequently produced mixed results. Some small studies reported: • improved sleep efficiency, • reduced sleep latency, • altered sleep architecture, • or subjective sleep improvement. Others failed to reproduce strong sleep-inducing effects. This led researchers to reconsider whether DSIP should actually be described as a direct hypnotic peptide. The best Aminodex summary is: DSIP has sleep-related biological activity, but evidence does not support treating it as a reliably established endogenous sleep hormone or conventional sleeping drug.
Pain
Animal experiments have investigated DSIP for effects on pain sensitivity and endogenous analgesic systems. Reported antinociceptive effects generated interest in possible interactions between DSIP and opioid/neuropeptide signaling. Human evidence is far less developed.
Withdrawal and substance dependence
DSIP was historically investigated in people experiencing withdrawal from alcohol or opioid dependence. Some small clinical reports described reductions in withdrawal symptoms and improvements in sleep. These studies are old, small, and difficult to interpret by modern clinical standards. They should be treated as exploratory evidence rather than proof of an addiction-treatment effect.
Epilepsy and neuronal excitability
DSIP has also been investigated in experimental epilepsy and seizure models. Some animal experiments reported anticonvulsant activity or changes in seizure thresholds. The mechanism remains uncertain. There is insufficient evidence to characterize DSIP as an established anticonvulsant therapy.
Circadian and neuroendocrine regulation
Because DSIP does not behave consistently as a straightforward hypnotic, researchers have proposed broader roles in: • Circadian regulation • Neuroendocrine coordination • Adaptation to stress • Hormonal rhythms • Homeostasis This broader interpretation fits the inconsistent sleep literature better than the simplistic claim that DSIP is “the peptide that makes you sleep.”
How Does It Work?
This is one of DSIP's biggest scientific mysteries. There is no well-established dedicated DSIP receptor comparable with GLP-1R, GHS-R1a, or other clearly defined peptide-receptor systems. Proposed effects involve: GABAergic signaling Some experimental findings suggest interactions with inhibitory neurotransmission. Opioid signaling DSIP may interact indirectly with endogenous opioid systems. HPA-axis regulation Effects involving ACTH and corticosteroid responses have been reported. Circadian systems DSIP may influence broader biological-rhythm regulation. Neurotransmitter modulation Experimental studies have suggested effects involving serotonin and other neurotransmitters. But none provides a complete accepted mechanism. That uncertainty should be visible on Aminodex rather than hidden.
What Does the Research Show?
Human research
Human research exists, which makes DSIP more than a purely animal research compound. Studies have investigated: • Insomnia • Sleep architecture • Chronic pain • Withdrawal • Neurological disorders However, most human studies are: • Old • Small • Methodologically heterogeneous • Difficult to reproduce • Conducted before modern trial-reporting standards There is no robust modern clinical evidence establishing DSIP as an approved treatment for insomnia or another condition.
Animal research
Animal evidence is considerably broader. Researchers have examined: • Slow-wave sleep • Circadian rhythm • Stress • Pain • Seizures • Hormonal responses • Neurotransmitter systems One of the most important lessons from this literature is actually the inconsistency. DSIP sometimes produces effects that depend heavily on: • Species • Baseline sleep state • Time of administration • Experimental conditions • Dose That is difficult to reconcile with the idea of a simple universal “sleep hormone.”
In-vitro research
Compared with many modern research peptides, DSIP's molecular pharmacology remains poorly defined. Researchers have investigated: • Peptide degradation • Binding interactions • Neuroendocrine effects • Neurotransmitter systems But no universally accepted DSIP-specific receptor has emerged. This is a major gap in the field.
Notable Studies
Delta Sleep-Inducing Peptide (DSIP): A Still Unresolved Story
humanHistorical and physiological literature concerning DSIP's proposed sleep and neuroendocrine functions. The source describes this as a review of the unresolved story of DSIP's proposed sleep and neuroendocrine functions. No year or PMID is given in the packet.
Limitations: No year, author, sample size, or PMID is provided in the source packet. Treat as a literature-review pointer, not a quantified modern trial.
View publication →What We Still Don't Know
Quite a lot: • Whether DSIP is truly an endogenous physiological sleep regulator • Where endogenous DSIP is produced • Whether a dedicated DSIP receptor exists • What its principal human mechanism is • Human pharmacokinetics • Whether exogenous DSIP reliably reaches relevant CNS targets • Whether it meaningfully improves insomnia • Whether it changes restorative sleep rather than EEG patterns alone • Long-term human safety • Dose-response relationships • Effects on circadian rhythm • Effects on stress physiology • Whether analgesic effects translate to humans • Whether historical withdrawal findings are reproducible • Why different experiments produce contradictory sleep effects
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Delta Sleep-Inducing Peptide research with you.
Get the Aminodex Delta Sleep-Inducing Peptide Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
Supplier Listings
Disclosure: The owner of Aminodex operates the supplier(s) marked below. These listings are promotion for businesses we own, not independent recommendations. Read our disclosures.